News Release

Frost & Sullivan New Product Innovation Award Recognizes OpGen’s Argus® Whole Genome Mapping System

08.18.11

Media Contact:
Dan Budwick
Pure Communications, Inc.
(973) 271-6085
dan@purecommunicationsinc.com

OpGen Contact:
Judy Macemon
VP Marketing, OpGen, Inc.
(240) 813-1279

GAITHERSBURG, Md.–(BUSINESS WIRE)–OpGen, Inc., a provider of innovative whole genome DNA analysis solutions, announced today the company was chosen to receive the Frost & Sullivan 2011 Best Practice Award for New Product Innovation. The annual Frost & Sullivan awards spotlight “best-in-class” companies based on excellence in managing growth, innovation and leadership, and are selected utilizing Frost & Sullivan’s global research organization of 1,800 analysts and consultants monitoring 300 industries and 250,000 companies.

“We are very pleased that Frost & Sullivan has recognized OpGen’s accomplishments in the successful development and commercialization of the Argus® Whole Genome Mapping System,” commented Doug White, CEO of OpGen. “Our recent success includes providing rapid and accurate whole genome maps of the German E. coli outbreak genome and a growing number of customers and publications that cite the value of incorporating whole genome maps to produce high quality de novo reference sequences.”

OpGen’s growing customer base includes high-profile genome centers such as Beijing Genome Institute and Wellcome Trust Sanger Institute as well as a number of research labs, bio-defense, government labs and public health institutions.

The New Product Innovation Awards in North America are presented to companies in a variety of industries that demonstrate excellence in the following categories: innovative element of the product, complimentary product leverage provided by the new product’s leading-edge technologies, value added features/benefits, increased customer ROI and customer acquisition or market penetration potential. Past recipients of Best Practice Awards include organizations such as Life Technologies, Bayer Diagnostics and Phillips Healthcare.

“The New Product Innovation Award recognizes the most innovative, market-changing technologies in the life science community,” notes industry analyst Christi Bird. “We expect OpGen’s Argus® System to become a vital tool in sequencing laboratories to drive efficiency and reduce costs of genome finishing.”

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, enables clients to accelerate growth and achieve best-in-class positions in growth, innovation and leadership. The company’s Growth Partnership Service provides the CEO and the CEO’s Growth Team with disciplined research and best-practice models to drive the generation, evaluation, and implementation of powerful growth strategies. Frost & Sullivan leverages 50 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 40 offices on six continents. To join our Growth Partnership, please visit http://www.awards.frost.com.

About OpGen, Inc.

OpGen, Inc. is a leading innovator in rapid, accurate genomic and DNA analysis systems and services. The company has developed a platform, the Argus® System, and also offers MapIt Services that provide high resolution, whole genome restriction maps for sequence assembly and finishing, strain typing and comparative genomics for life sciences applications. This proprietary de novo technology is not constrained by the limitations of gel, PCR and sequencing-based methodologies. Applications to expand OpGen’s whole genome mapping technology to large genomes and clinical diagnostics are currently in development. OpGen’s customers include leading genome research centers, biodefense organizations, academic institutions, clinical research organizations and biotechnology companies. For more information, visit www.gbbetasite.com/opgen.